MACK - Merrimack Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.1900
+0.4900 (+18.15%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close2.7000
Open3.0600
Bid0.0000 x 2200
Ask0.0000 x 1200
Day's range2.8800 - 3.2000
52-week range1.4900 - 6.1900
Volume138,035
Avg. volume38,601
Market cap42.683M
Beta (5Y monthly)1.80
PE ratio (TTM)N/A
EPS (TTM)-1.2980
Earnings date07-May-2020 - 11-May-2020
Forward dividend & yieldN/A (N/A)
Ex-dividend date12-Dec-2019
1y target est4.00
  • Business Wire

    Merrimack Divests Early Stage Asset for $2.25 Million; Provides Strategy Update

    Merrimack Announces Sale Of Early Stage Asset for $2.25 Million And Provides Strategy Update.

  • GlobeNewswire

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Merrimack Pharmaceuticals, Inc. - MACK

    Pomerantz LLP is investigating claims on behalf of investors of Merrimack Pharmaceuticals, Inc. (“Merrimack” or the “Company”) (NASDAQ: MACK).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. On April 4, 2019, Merrimack announced the discontinuation of work on its sole drug candidate in clinical trials, MM-310, citing safety issues.  Despite amending the protocol for its Phase 1 study after observing and disclosing signs of peripheral neuropathy in clinical trial participants beginning in November, Merrimack reported that subjects taking MM-310 continued to experience weakness, numbness and extremity pain associated with peripheral neuropathy.  On this news, Merrimack’s stock price fell $1.18 per share, or 16.41%, to close at $6.01 per share on April 5, 2019.